CCZ1/CCZ1B Antibody

What applications are validated for CCZ1/CCZ1B antibodies and what are the recommended dilutions?

CCZ1/CCZ1B antibodies have been validated for multiple applications, with specific optimal dilutions:

Best practices include:

• For Western blotting, use a gradient of dilutions to determine optimal signal-to-noise ratio for your specific sample type

• For immunofluorescence, fixation method can significantly impact epitope accessibility; both paraformaldehyde and methanol fixation should be tested when working with lysosomal membrane proteins like CCZ1

• When using conjugated antibodies (HRP, FITC, PE), reduce exposure to light to prevent photobleaching

How can I confirm the specificity of a CCZ1/CCZ1B antibody in my experimental system?

To validate antibody specificity:

• Include appropriate positive controls:

  • Human, mouse, or rat samples are suitable for most commercial CCZ1 antibodies

  • Lysosomal-enriched fractions provide concentrated target protein

• Include negative controls:

  • CRISPR/Cas9 CCZ1 knockout cells serve as definitive negative controls

  • siRNA knockdown samples (showing proportional reduction in signal)

• Validation approaches:

  • Western blot should show a single band at approximately 55.9 kDa

  • For critical experiments, use multiple antibodies targeting different epitopes

  • Cross-validate results using complementary techniques (e.g., mass spectrometry has been used to validate CCZ1 knockout models)

• Expected results:

  • CCZ1 protein typically shows strongest expression in lysosomal membrane fractions

  • Subcellular localization studies should show colocalization with other lysosomal markers

What sample preparation methods optimize detection of CCZ1/CCZ1B in different applications?

Optimal sample preparation varies by application:

For Western Blotting:

• Use RIPA buffer with protease inhibitors for total protein extraction

• Include phosphatase inhibitors if studying regulatory modifications

• Membrane protein enrichment techniques improve detection of lysosomal membrane-associated CCZ1

• Avoid high temperatures during sample preparation as they may cause protein aggregation

For Immunofluorescence:

• Gentle permeabilization is crucial for accessing lysosomal membrane proteins

• 0.1-0.2% Triton X-100 or 0.1% saponin recommended for permeabilization

• Co-staining with LAMP1 antibodies helps confirm lysosomal localization

• Both methanol and PFA fixation protocols have been successfully used

For Co-Immunoprecipitation:

• Crosslinking may be necessary to capture transient interactions with Rab7, Mon1, or other binding partners

• NP-40 or digitonin-based buffers better preserve protein complexes compared to stronger detergents

How can CCZ1/CCZ1B antibodies be used to investigate the Mon1-Ccz1-RMC1 complex in endolysosomal trafficking research?

The Mon1-Ccz1-RMC1 complex is critical for Rab5 to Rab7 conversion during endosome maturation. Advanced research applications include:

• Complex assembly analysis:

  • Use co-immunoprecipitation with CCZ1 antibodies to pull down Mon1A/B and RMC1 components

  • Sequential immunoprecipitation can isolate intact complexes from cellular lysates

• Structural investigation approaches:

  • CCZ1 antibodies can verify protein expression and complex formation prior to structural studies

  • Antibody epitope mapping can complement cryo-EM data on domain organization

• Functional studies:

  • Immunofluorescence co-localization of CCZ1 with early/late endosomal markers provides kinetic information

  • In vitro GEF activity assays can be validated using immunodepleted samples

• Methodological considerations:

  • When studying complex components, knockdown of one component (e.g., CCZ1) often affects stability of partners (Mon1, RMC1)

  • Antibodies targeting different complex components should be used to verify results

  • Early endosome antigen 1 (EEA1) and LAMP1 serve as reliable markers for endosomal maturation studies

Research has demonstrated that disruption of the complex through CCZ1 knockout leads to enlarged early endosomes (approximately 2.5 times normal size), suggesting impaired maturation .

What are the methodological considerations when using CCZ1/CCZ1B antibodies to study viral infection mechanisms?

CCZ1 has been identified as an essential host factor for filovirus (Marburg, Ebola) and SARS-CoV-2 infections. Key methodological approaches include:

• Infection models compatible with CCZ1 antibody detection:

  • Cell line models: A549 cells show consistent CCZ1 expression

  • 3D primary human hepatocyte cultures

  • Human blood-vessel organoids

• Experimental design considerations:

  • Time course experiments should include early time points (1-6h) to capture virus trafficking events

  • Co-immunostaining of viral proteins and CCZ1 reveals co-localization during trafficking

  • Knockdown efficiency should be verified by Western blot (>50% reduction in protein level is typically needed for functional effects)

• Controls and validation:

  • CRISPR/Cas9 CCZ1 knockout cells provide definitive controls

  • Rescue experiments with CCZ1 expression constructs confirm specificity

  • MON1A/B knockout cells show similar but not identical phenotypes (89.4% and 82.4% reduction in infection, respectively)

• Advanced techniques:

  • Live cell imaging with fluorescently-tagged CCZ1 antibody fragments can track trafficking

  • Electron microscopy with immunogold-labeled CCZ1 antibodies provides ultrastructural localization

  • Mass spectrometry of CCZ1-immunoprecipitated samples can identify virus-specific interaction partners

Published research shows that CCZ1 knockout results in >98% reduction in Marburg virus infection and >90% reduction in Ebola virus infection, while having no impact on Lassa virus (which enters at the late endosome stage) .

How can discrepancies in CCZ1/CCZ1B antibody detection between different assays be resolved?

Researchers may encounter inconsistencies between different detection methods. Resolution approaches include:

• Epitope accessibility issues:

  • Different antibodies target distinct epitopes that may be masked in certain contexts

  • Solution: Use multiple antibodies targeting different regions of CCZ1/CCZ1B

  • For conformational epitopes, native conditions may be required for detection

• Antibody validation strategies:

  • Sequence-based validation: Confirm antibody specificity against CCZ1 vs CCZ1B paralog

  • Mass spectrometry validation: Confirm protein identity in immunoprecipitated samples

  • Functional validation: Complement antibody detection with functional assays (e.g., Rab7 activation)

• Technical troubleshooting:

  • For weak Western blot signals: Optimize lysis buffers for membrane protein extraction

  • For immunofluorescence: Test different fixation and permeabilization methods

  • For immunoprecipitation: Consider crosslinking to stabilize transient interactions

• Biological explanations for discrepancies:

  • Post-translational modifications may affect epitope recognition

  • Protein complex formation may mask antibody binding sites

  • CCZ1 stability depends on complex formation with Mon1 and potentially RMC1

What approaches can be used to study CCZ1/CCZ1B involvement in autophagy using available antibodies?

CCZ1 has been implicated in autophagy regulation through its role in Rab7 activation. Research methodologies include:

• Autophagy flux assessment:

  • Western blot analysis of LC3-II and SQSTM1/p62 in CCZ1 knockout vs. wild-type cells

  • CCZ1 depletion leads to accumulation of both LC3-II and p62, indicating impaired autophagic flux

  • Antibodies against CCZ1, LC3, and p62 can be used on the same membrane with appropriate stripping

• Autophagosome-lysosome fusion visualization:

  • Co-immunofluorescence of CCZ1 with LC3 and LAMP1

  • Analysis of colocalization coefficients in control vs. treated conditions

  • Live-cell imaging with fluorescently tagged markers

• Rescue experiments:

  • Complementation with wild-type vs. mutant CCZ1 constructs

  • Mutations targeting the Mon1-interaction interface (L576A/R580E/R583E or D605R/Y610A) fail to rescue enlarged endolysosomal phenotypes

  • Expression level quantification via Western blot ensures comparable protein levels

• Advanced techniques:

  • Proximity ligation assay (PLA) to detect interactions between CCZ1 and autophagy machinery

  • CLEM (Correlative Light and Electron Microscopy) with CCZ1 immunolabeling to visualize ultrastructural features

Research shows that RMC1 depletion (a CCZ1 complex component) leads to significant accumulation of autophagy markers, suggesting that the entire Mon1-Ccz1-RMC1 complex is critical for maintaining normal autophagic flux .

How can I optimize CCZ1/CCZ1B antibody usage in 3D organoid models?

Organoid models provide physiologically relevant systems for studying CCZ1 function. Optimization strategies include:

• Sample processing considerations:

  • Modified fixation protocols for penetration into 3D structures:

    • Longer fixation times (e.g., 1-2 hours) with 4% paraformaldehyde

    • Enhanced permeabilization (0.2-0.3% Triton X-100 for 30-60 minutes)

  • Clearing techniques may improve antibody penetration and imaging depth

• Validated organoid systems:

  • Primary human hepatocyte spheroids

  • Human blood-vessel organoids derived from iPSCs

  • Both systems show CCZ1-dependent phenotypes for filovirus infection

• Technical adaptations:

  • For Western blotting: Pool multiple organoids (25-30) for sufficient protein extraction

  • For RNA analysis: Use TRIzol-based extraction from pooled samples (3-5 organoids)

  • For immunofluorescence: Extended antibody incubation (overnight at 4°C) improves penetration

• Data analysis considerations:

  • 3D imaging analysis requires specialized software for accurate quantification

  • Thickness of optical sections affects signal intensity

  • Controls should match experimental samples in size and morphology

Research has shown that CCZ1 knockdown in primary human hepatocyte spheroids reduces filovirus infection by 68.5-74.1%, while CCZ1 knockout in blood vessel organoids reduces infection by >99% .

What are the considerations for using CCZ1/CCZ1B antibodies in model organisms beyond human samples?

CCZ1 is evolutionarily conserved across eukaryotes, but antibody cross-reactivity requires validation:

• Validated cross-reactivity:

  • Human, mouse, rat, and monkey samples have been validated for many commercial antibodies

  • Sequence homology does not guarantee antibody recognition

• Non-mammalian model considerations:

  • S. cerevisiae (yeast): CCZ1 antibodies may require species-specific validation

  • Chaetomium thermophilum (fungal model): 15% sequence identity with human CCZ1, limiting antibody cross-reactivity

  • Drosophila melanogaster: Has been used for structural studies of the Mon1-Ccz1-RMC1 complex

• Comparative studies approach:

  • Choose antibodies raised against conserved epitopes

  • Western blot should be performed first to confirm specificity in each species

  • Positive and negative controls should be included for each new species

• Technical adaptations:

  • Fixation protocols may need optimization for different tissues/species

  • Antigen retrieval methods vary by species and tissue type

  • Secondary antibody selection should account for species cross-reactivity

The structure of the Mon1-Ccz1 complex has been studied across species, revealing functional conservation despite sequence divergence. The complex adopts a pseudo twofold symmetry with three triangularly organized longin domains (LDs) in each component .

How can I quantitatively assess CCZ1 protein expression and activity in cellular systems?

For quantitative analysis of CCZ1 expression and function:

• Absolute protein quantification:

  • Scheduled PRM (Parallel Reaction Monitoring) mass spectrometry

  • Reference: Study used 9 unique trypsin-specific peptides for CCZ1 identification

  • Western blot with recombinant protein standards for calibration

• Functional activity assessment:

  • Rab7 activation assays (measure GTP-bound Rab7)

  • Endosome maturation kinetics via live cell imaging

  • Cholesterol transport efficiency (NPC1-dependent pathway)

• Cellular phenotype quantification:

  • Endosomal size measurements (early endosomes enlarge ~2.5x in CCZ1 KO cells)

  • Lysosomal distribution patterns

  • Co-localization coefficients with Rab5 (early endosomes) vs. Rab7 (late endosomes)

• Data normalization approaches:

  • For Western blot: Normalize to housekeeping proteins and total protein stains

  • For microscopy: Use algorithm-based quantification rather than manual assessment

  • For functional assays: Include internal standards across experiments

Data from mass spectrometry studies has been used to validate CCZ1 knockout models, providing definitive confirmation of protein absence in genetic models .

What protocols are recommended for studying CCZ1-dependent protein complexes using co-immunoprecipitation?

The CCZ1 protein functions within multi-protein complexes. Optimal co-IP approaches include:

• Buffer optimization for complex preservation:

  • Mild detergent buffers (0.5-1% NP-40 or 0.5% digitonin)

  • Physiological salt concentration (150 mM NaCl)

  • Protease inhibitor cocktails to prevent degradation

  • Low temperature processing throughout

• Validated protein-protein interactions:

  • CCZ1-Mon1A/B: Core complex components

  • CCZ1-RMC1: Metazoan-specific interaction

  • CCZ1-Rab7: Functional interaction (GEF activity)

  • CCZ1-HOPS complex: Broader trafficking machinery

• Technical considerations:

  • Pre-clearing lysates reduces non-specific binding

  • Protein A/G selection affects antibody binding efficiency

  • Elution methods impact complex integrity (native vs. denaturing)

  • Cross-linking may be necessary for transient interactions

• Controls and validation:

  • Input controls (5-10% of lysate)

  • IgG isotype controls

  • Reciprocal IPs with antibodies to different complex components

  • Validation using mutant constructs with known interaction defects

Research has identified specific residues critical for complex formation: mutations in RMC1 (H519A/Q520A/Y524A) and (Q549A/D553R/R558E) disrupt interaction with both Mon1B and CCZ1, suggesting cooperative binding .

How can I address non-specific binding issues with CCZ1/CCZ1B antibodies?

Non-specific binding can compromise experimental results. Resolution strategies include:

• Western blot optimization:

  • Increase blocking time/concentration (5% BSA or milk for 1-2 hours)

  • Optimize primary antibody dilution (start with manufacturer recommendation, then test 2-fold dilution series)

  • Increase washing stringency (0.1-0.2% Tween-20 in TBS/PBS)

  • Consider alternative membrane types (PVDF vs. nitrocellulose)

• Immunofluorescence improvements:

  • Pre-adsorb antibodies with cell/tissue lysates from knockout samples

  • Use species-matched normal serum in blocking buffer

  • Reduce primary antibody concentration

  • Include detergent (0.1% Triton X-100) in antibody diluent

• Validation using genetic models:

  • CCZ1 CRISPR knockout cells provide definitive negative controls

  • siRNA knockdown (52.6% protein reduction observed in published studies)

  • Complementation with expression constructs should restore specific signal

• Technical considerations:

  • Secondary antibody cross-reactivity can be assessed with secondary-only controls

  • Batch-to-batch antibody variation may necessitate revalidation

  • Detection system sensitivity should match application requirements

What are the best approaches for long-term storage and handling of CCZ1/CCZ1B antibodies to maintain activity?

Proper antibody handling ensures consistent results across experiments:

• Storage recommendations:

  • Most CCZ1/CCZ1B antibodies are supplied in buffers containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide

  • Store at -20°C for long-term stability (avoid repeated freeze-thaw cycles)

  • For frequent use, small working aliquots can be maintained at 4°C for 1-2 weeks

  • Avoid exposure to light for fluorochrome-conjugated antibodies

• Handling best practices:

  • Centrifuge briefly before opening to collect liquid

  • Use sterile technique to prevent contamination

  • Avoid vortexing (gentle mixing only)

  • Use non-stick tubes for diluted antibodies to prevent adsorption

• Quality control monitoring:

  • Document lot numbers and include consistent positive controls

  • Periodically validate antibody performance against reference samples

  • Monitor for changes in background or signal intensity over time

  • Consider preparing master mixes for large experiments to ensure consistency

• Reconstitution and dilution:

  • Follow manufacturer's recommendations for reconstitution of lyophilized antibodies

  • Use high-quality, filtered buffers for dilutions

  • Include carrier protein (0.1-0.5% BSA) in working dilutions

  • Record date of reconstitution/first use on antibody containers

How can I validate antibody specificity when studying both CCZ1 and its paralog CCZ1B simultaneously?

CCZ1 and CCZ1B paralogs present challenges for specific detection:

• Sequence analysis approach:

  • Identify regions of sequence divergence between CCZ1 and CCZ1B

  • Determine antibody epitope locations when possible

  • Epitope mapping can be performed using peptide arrays or truncation constructs

• Expression pattern analysis:

  • CCZ1 and CCZ1B show differential tissue expression patterns

  • Use tissue-specific expression data to validate antibody specificity

  • Both paralogs localize to the lysosomal membrane

• Genetic validation methods:

  • Generate paralog-specific knockouts using CRISPR/Cas9

  • Target both paralogs simultaneously with gRNAs targeting common regions

  • Use siRNA with validated specificity for each paralog

• Technical validation:

  • Western blot mobility differences (if present)

  • Immunoprecipitation followed by mass spectrometry

  • Peptide competition assays with paralog-specific peptides

  • Recombinant protein controls for each paralog

Research has demonstrated successful generation of double knockout cell lines targeting both CCZ1 and CCZ1B paralogs using CRISPR/Cas9 with gRNAs designed to target both genes .